| Implementation strategy number 1: patients from non-responsive sites randomized to first receive 6 months of Enhanced REP (immediate) (N  = 1,543) | Implementation strategy number 2: patients from non-responsive sites randomized to first receive 6 months of Standard REP (delayed) (N  = 1,532) | Unadjusted OR (95% CI) | Adjusted ORa(95% CI) |
---|---|---|---|---|
Cumulative outcomes assessed over the 12-month period (August 31, 2012–August 31, 2013) | ||||
 Updated status | 848 (54.96%) | 613 (40.01%) | 1.18 (0.43, 3.28) | 1.29 (0.43, 3.90) |
 Attempted contact | 694 (44.98%) | 491 (32.05%) | 1.06 (0.44, 2.59) | 1.13 (0.44, 2.93) |
 Completed contact | 198 (12.83%) | 142 (9.27%) | 1.26 (0.72, 2.18) | 1.31 (0.70, 2.43) |
Health-care use | ||||
 Any outpatient use | 358 (23.20%) | 382 (24.93%) | 0.90 (0.70, 1.16) | 0.94 (0.72, 1.22) |
 Any inpatient use | 56 (3.63%) | 58 (3.79%) | 0.97 (0.62, 1.54) | 1.00 (0.66, 1.51) |
 Any inpatient or outpatient use | 361 (23.40%) | 383 (25.00%) | 0.91 (0.71, 1.17) | 0.94 (0.72, 1.23) |
Outcomes in first 6 months of implementation intervention (August 31, 2012–February 28, 2013) | ||||
 Updated status | 605 (39.21%) | 262 (17.10%) | 2.85 (0.99, 8.25) | 2.81 (0.93, 8.54) |
 Attempted contact | 479 (31.04%) | 207 (13.51%) | 2.15 (0.81, 5.71) | 2.21 (0.80, 6.05) |
 Completed contact | 121 (7.84%) | 57 (3.72%) | 1.94 (1.01, 3.74)* | 2.13 (1.09, 4.19)* |
Health-care use | ||||
 Any outpatient use: August 31 2012–February 28 2013 | 234 (15.17%) | 256 (16.71%) | 0.89 (0.69, 1.16) | 0.95 (0.73, 1.24) |
 Any inpatient use | 40 (2.59%) | 43 (2.81) | 0.89 (0.54, 1.46) | 0.89 (0.53, 1.49) |
 Any inpatient or outpatient use | 237 (15.36%) | 257 (16.78%) | 0.91 (0.70, 1.17) | 0.96 (0.74, 1.25) |
Outcomes in second 6 months of implementation intervention (March 1, 2013–August 31, 2013) | ||||
 Updated status | 243 (15.75%) | 351 (22.91%) | 0.30 (0.11, 0.84)* | 0.33 (0.12, 0.91)* |
 Attempted contact | 215 (13.93%) | 284 (18.54%) | 0.39 (0.15, 1.08) | 0.43 (0.16, 1.19) |
 Completed contact | 77 (4.99%) | 85 (5.55%) | 0.58 (0.26, 1.30) | 0.61 (0.25, 1.49) |
Health-care use | ||||
 Any outpatient use: March 1 2013–August 31 2013 | 276 (17.89%) | 290 (18.93%) | 0.96 (0.72, 1.28) | 0.99 (0.74, 1.34) |
 Any inpatient use | 28 (1.81%) | 30 (1.96%) | 0.92 (0.51, 1.65) | 0.99 (0.56, 1.72) |
 Any inpatient or outpatient use | 278 (18.02%) | 291 (18.99%) | 0.96 (0.72, 1.28) | 0.99 (0.74, 1.33) |